Treatment patterns in rheumatoid arthritis patients newly initiated on biologic and conventional synthetic disease-modifying antirheumatic drug therapy and enrolled in a North American clinical registry

被引:9
|
作者
Mease, Philip J. [1 ,2 ]
Stryker, Scott [3 ]
Liu, Mei [4 ]
Salim, Bob [5 ]
Rebello, Sabrina [4 ]
Gharaibeh, Mahdi [3 ]
Collier, David H. [3 ]
机构
[1] Providence St Joseph Hlth, Swedish Med Ctr, Seattle, WA 98122 USA
[2] Univ Washington, Seattle, WA 98122 USA
[3] Amgen Inc, Thousand Oaks, CA 91320 USA
[4] Corrona LLC, Waltham, MA USA
[5] Axio Res LLC, Seattle, WA USA
关键词
Disease-modifying antirheumatic drug; Etanercept; Rheumatoid arthritis; US Corrona registry; DOUBLE-BLIND; METHOTREXATE; MONOTHERAPY; COMBINATION; ETANERCEPT; INHIBITOR; MODERATE; ADALIMUMAB; FILGOTINIB; MANAGEMENT;
D O I
10.1186/s13075-021-02599-4
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Understanding the evolving treatment patterns in patients with rheumatoid arthritis (RA) is important for rheumatologists to make the best practice decisions and optimize treatment. Here, we describe treatment patterns among patients newly initiated on biologic and/or nonbiologic RA therapy over time after enrollment in the US Corrona RA registry. Methods This was a retrospective, cohort study of adult patients with RA enrolled in the Corrona RA registry. Patients were included in this study if they initiated therapy with conventional synthetic disease-modifying antirheumatic drug (csDMARD) monotherapy, TNF inhibitor (TNFi) monotherapy, other (non-TNFi) biologic monotherapy, or combination therapy (index therapy); initiated therapy between January 1, 2004, and December 31, 2015 (index date), after enrollment in the Corrona RA registry; had at least 6 months of follow-up time after the index date; and had at least one follow-up visit. Time periods of interest were based on the year of index therapy initiation: 2004-2007, 2008-2011, and 2012-2015. Results This study included 8027 patients. csDMARD monotherapy and TNFi + csDMARD combination therapy were the most common index therapies in the registry (39.9% and 44.9%, respectively, in the 2004-2007 period; 38.6% and 38.2%, respectively, in the 2008-2011 period; and 35.2% for both in the 2012-2015 period). At therapy initiation, a higher proportion of patients who initiated other biologics, whether as monotherapies (54.0%) or in combination with csDMARD (49.9%), had high disease activity than those who initiated csDMARD monotherapy (28.4%). For 2012-2015 vs 2004-2007 and 2008-2011 periods, persistence on a given therapy appeared to decrease for the TNFi monotherapy cohort (48.2% vs 64.3% and 52.4%) and other biologic monotherapy cohort (52.3% vs 71.4% and 54.5%) over 12 months; switching from one therapy to another was common in the Corrona RA registry. Conclusions Increased switching from one therapy to another and decreased time on a given therapy was observed in the Corrona RA registry in the 2012-2015 period. This observation is most likely due to the increased availability of additional treatment options and/or the change in clinical focus, particularly the emphasis on achievement of treat-to-target goals of remission or low disease activity along with more aggressive treatment.
引用
下载
收藏
页数:13
相关论文
共 50 条
  • [31] Disease-modifying antirheumatic drug prescription patterns in adult rheumatoid arthritis patients in routine clinical practice in Spain
    Hernandez Cruz, Blanca
    Urena Garnica, Inmaculada
    Sanchez Parera, Ricardo
    Rubio Romero, Esteban
    Calvo Gutierrez, Jerusalen
    Garcia Sanchez, Antonio
    Rodriguez Escalera, Carlos
    Navarro Sarabia, Federico
    EUROPEAN JOURNAL OF RHEUMATOLOGY, 2020, 7 (04) : 149 - 157
  • [32] Utilization of Biologic Disease-Modifying Antirheumatic Therapy in Patients With Rheumatoid Arthritis and Recently Diagnosed Breast Cancer
    Ruiz, Juan I.
    Lei, Xiudong
    Wu, Chi-Fang
    Zhao, Hui
    Giordano, Sharon H.
    Rajan, Suja S.
    Suarez-Almazor, Maria E.
    ARTHRITIS CARE & RESEARCH, 2024, 76 (06) : 850 - 859
  • [33] Overall survival in patients with rheumatoid arthritis and solid malignancies receiving biologic disease-modifying antirheumatic therapy
    Xerxes Pundole
    Natalia V. Zamora
    Harish Siddhanamatha
    Heather Lin
    Jean Tayar
    Cheuk Hong Leung
    Liang Li
    Maria E. Suarez-Almazor
    Clinical Rheumatology, 2020, 39 : 2943 - 2950
  • [34] Overall survival in patients with rheumatoid arthritis and solid malignancies receiving biologic disease-modifying antirheumatic therapy
    Pundole, Xerxes
    Zamora, Natalia V.
    Siddhanamatha, Harish
    Lin, Heather
    Tayar, Jean
    Leung, Cheuk Hong
    Li, Liang
    Suarez-Almazor, Maria E.
    CLINICAL RHEUMATOLOGY, 2020, 39 (10) : 2943 - 2950
  • [35] Ultrasonographic Efficacy of Biologic and Targeted Synthetic Disease-Modifying Antirheumatic Drug Therapy in Rheumatoid Arthritis From a Multicenter Rheumatoid Arthritis Ultrasound Prospective Cohort in Japan
    Nishino, Ayako
    Kawashiri, Shin-ya
    Koga, Tomohiro
    Iwamoto, Naoki
    Ichinose, Kunihiro
    Tamai, Mami
    Nakamura, Hideki
    Origuchi, Tomoki
    Ueki, Yukitaka
    Yoshitama, Tamami
    Eiraku, Nobutaka
    Matsuoka, Naoki
    Okada, Akitomo
    Fujikawa, Keita
    Hamada, Hiroaki
    Tsuru, Tomomi
    Nagano, Shuji
    Arinobu, Yojiro
    Hidaka, Toshihiko
    Kawakami, Atsushi
    ARTHRITIS CARE & RESEARCH, 2018, 70 (12) : 1719 - 1726
  • [36] BURDEN OF MALIGNANCY, VENOUS THROMBOEMBOLISM, ANEMIA, AND INFECTIONS IN PATIENTS WITH RHEUMATOID ARTHRITIS WHO SWITCHED FROM A FIRST CONVENTIONAL SYNTHETIC DISEASE-MODIFYING ANTIRHEUMATIC DRUG TO ANOTHER DISEASE-MODIFYING ANTIRHEUMATIC DRUG REGIMEN
    Dore, R. K.
    Antonova, J.
    Chang, L.
    Huang, H.
    Kim, H.
    Genovese, M. C.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 962 - 963
  • [37] BONE STATUS OF RHEUMATOID ARTHRITIS PATIENTS TREATED WITH BIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS
    Miladi, S.
    Ben Ayed, H.
    Makhlouf, Y.
    Boussaa, H.
    Ouenniche, K.
    Souabni, L.
    Kassab, S.
    Chekili, S.
    Ben Abdelghani, K.
    Fazaa, A.
    Laatar, A.
    AGING CLINICAL AND EXPERIMENTAL RESEARCH, 2023, 35 : S447 - S447
  • [38] Incidence of Interstitial Lung Disease in Patients With Rheumatoid Arthritis Treated With Biologic and Targeted Synthetic Disease-Modifying Antirheumatic Drugs
    Baker, Matthew C.
    Liu, Yuhan
    Lu, Rong
    Lin, Janice
    Melehani, Jason
    Robinson, William H.
    JAMA NETWORK OPEN, 2023, 6 (03)
  • [39] Factors Associated with the Use of Biologic Disease-modifying Antirheumatic Drugs in Patients with Rheumatoid Arthritis
    Hosseini, Roya
    Fawaz, Souhiela
    Seoane-Vazquez, Enrique
    ARTHRITIS & RHEUMATOLOGY, 2021, 73 : 2595 - 2595
  • [40] Treatment failure with disease-modifying antirheumatic drugs in rheumatoid arthritis patients
    Mittal, Niti
    Mittal, Rakesh
    Sharma, Aman
    Jose, Vinu
    Wanchu, Ajay
    Singh, Surjit
    SINGAPORE MEDICAL JOURNAL, 2012, 53 (08) : 532 - 536